RxDoctor Payments Data

Amylie Rojas, MD

Family Medicine · Tamuning, GUNPI 1104489475

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Exact Sciences at 34.7% of the total. Reporting peaked in 2024 at $514 and has fallen 89.4% since, to $54 in 2025.

$1,073in general payments, 2019–2025

Across 55 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$373
  • Novo Nordisk$170
  • Pfizer$89
  • Lilly USA, LLC$71
  • Sumitomo Pharma America, Inc.$61
  • Boehringer Ingelheim$56
  • plus $255 from 9 others

What the payments were for

  • Food & beverage$1,073100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few family medicine providers in Guamto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$84,188
Medicare patients
187
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$38,579
EliquisApixaban16$24,618
SynthroidLevothyroxine Sodium37$2,982
Levothyroxine Sodium143$1,493
Atorvastatin Calcium141$1,441
Rosuvastatin Calcium102$1,128
Estradiol17$894
Pravastatin Sodium40$855
Losartan Potassium83$838
Pantoprazole Sodium77$718
Omeprazole33$667
Gabapentin22$654
Albuterol Sulfate HfaAlbuterol Sulfate16$636
Nebivolol Hcl13$609
Amlodipine Besylate92$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$56$38,57929 claims
PfizerEliquis$89$24,61816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family medicine providers in Guamon file to place this against a meaningful peer group, so we don't.

Other family medicine in Tamuning

See the full list for Guam

Where these figures come from

Is this you, or does something look wrong? →